Widespread US shift from prescription to OTC lies in pharma’s hands
While the FDA maintains the legal right to make prescription meds OTC, legal expert Heidi Gertner believes that this wider shift depends on pharma’s engagement.
Biophytis and LynxKite expand alliance to boost AI-driven drug discovery
Vima banks $100m in Series A to progress Parkinson’s drug
WHO directs antibiotic development to priority pathogens
Parkinson’s research reaches “pivotal” stage, but barriers remain
PRISM BioLab partners with Receptor.AI for molecule discovery
Analysis
View More
Themes
View MoreCinnaGen Enters EU Market with EMA Approval for Zandoriah®
CinnaGen today announced that the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of Zandoriah® (teriparatide),…
More themes
Data Insights
View MoreCell & gene therapy: the leading companies in recombinant AAV gene therapy revealed
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
Eli Lilly and NVIDIA to build pharma’s “most powerful” supercomputer
Huawei’s three key steps to drive industrial intelligence forward and unleash AI’s full potential
First responders see AI and other advanced tech as essential
What does the EU Data Act mean for businesses?